How Effective Is the LEEP Procedure for CIN 3?

LEEP cures CIN 3 in roughly 88 to 97 percent of cases, depending on the study and how “cure” is defined. That puts it firmly among the most effective outpatient treatments for high-grade cervical precancer. But the headline number only tells part of the story, because the roughly 5 to 8 percent of women who experience recurrence are not a random group. Their outcomes depend heavily on whether HPV clears after the procedure, what the surgical margins look like, and a handful of other factors that shape how useful LEEP actually is for any individual person.

What the Cure Rate Looks Like Across Studies

A study of 386 women treated with LEEP for cervical precancer or early invasive disease found an 87.8 percent cure rate after the first excision, consistent with the 73 to 99 percent range reported in earlier research. Of those who were not cured, about 7.8 percent had persistent disease (abnormal cells still present at follow-up) and 4.4 percent had recurrence (initially clear, then abnormal cells returned).¹ A Chinese cohort study tracking over 4,300 women who had LEEP for high-grade lesions found a recurrence rate for CIN 2 or worse of about 5 percent at two years, climbing slightly to 6.1 percent by five years.² A separate study following LEEP patients for five years placed the recurrence rate slightly higher, at about 8 percent, and identified a CIN 3 diagnosis specifically as one of the strongest predictors of that recurrence.³

One newer cohort from China that compared LEEP directly against other treatment methods reported an even higher cure rate for CIN 3 specifically: 97 percent, compared with 94 percent for cold-knife conization and only 66 percent for thermal ablation.⁴ That wide gap between LEEP and ablation matters, because ablation is sometimes offered as a simpler alternative. For CIN 3, the evidence suggests excisional procedures like LEEP are strongly preferred.

Why HPV Clearance Matters More Than You Might Think

When people ask how effective LEEP is, the assumption is that success depends on whether the surgeon “got it all.” Surgical margins are part of the picture, but the virus itself is at least as important. A meta-analysis looking specifically at patients who had clear (negative) margins after LEEP found that if HPV also cleared, the recurrence rate dropped to around half a percent. But when HPV persisted despite negative margins, the recurrence rate jumped to about 18 percent. Women with lingering HPV had roughly 3.6 times the recurrence risk of those who cleared the virus.⁵

An earlier study confirmed this pattern in a different way. Among women treated with LEEP for CIN 2 or CIN 3, the recurrence risk did not vary by age or the specific CIN grade. What predicted recurrence was whether HPV was still detectable at follow-up and whether the first post-treatment Pap smear was abnormal.⁶ This is why follow-up protocols now rely heavily on HPV testing rather than cytology alone to decide whether a treated patient needs closer monitoring or re-treatment.

Other Factors That Predict Recurrence

Beyond HPV persistence, several factors raise the odds that CIN will come back after LEEP. A nationwide cohort study found that being over 60 at the time of treatment carried a higher recurrence risk compared with women treated in their 30s. More telling, the single strongest predictor was the result of the first follow-up Pap smear. Women whose first post-treatment Pap showed high-grade abnormalities had more than three times the risk of recurrence, and those with any abnormal Pap result within the first year had a progressively escalating risk, reaching over twelve times the baseline when the first-year result was high-grade.⁷

Surgical margin status also plays a role, though not as dominant a one as people expect. Positive margins (meaning abnormal cells were found at the edge of the tissue removed) are associated with residual disease. A study evaluating factors behind margin positivity found significant links to postmenopausal status, higher clinical severity scores, and involvement of the inner margin specifically.⁸ When CIN 3 patients with positive ectocervical margins underwent repeat LEEP, nearly half had CIN 3 still present, and about 11 percent had microinvasive cancer found in the second specimen.⁹ That last finding is a reminder that positive margins after CIN 3 treatment are not something to watch and wait on casually.

Long-Term Cancer Risk After CIN 3 Treatment

LEEP for CIN 3 is meant to prevent cervical cancer, and it overwhelmingly does. But “treated” does not mean “risk-free.” A large population-based study following over 80,000 women with a CIN 3 history found that about 0.5 percent eventually developed cervical cancer. Compared with the general female population, treated CIN 3 patients carried roughly twice the background risk of cervical cancer. That risk was not evenly distributed: women diagnosed with CIN 3 after age 50 had about seven times the general population risk, and those who developed recurrent CIN 3 had about nine times the risk.¹⁰ The researchers noted that much of the elevated risk over 20 years of follow-up appeared attributable to aging itself.

Reassuringly, a separate study looking at cancer-free survival after treatment for CIN found no significant differences between treatment methods. Whether women had been treated by LEEP, cold-knife conization, or other methods, their likelihood of remaining cancer-free was statistically comparable.¹¹ The take-home point is that long-term surveillance matters regardless of how the initial treatment was done, especially for women who were older at diagnosis or who have recurrent high-grade lesions.

LEEP Versus Cold-Knife Conization

The comparison that comes up most often is LEEP versus cold-knife conization (CKC), a more traditional surgical approach that uses a scalpel instead of an electrified wire loop. The practical differences are real: LEEP is faster, causes less bleeding during surgery, and results in shorter recovery time.¹² But does that speed trade off against effectiveness?

The answer is: it depends on which study you read. An older meta-analysis comparing the two found no statistically significant differences in recurrence rate, positive margins, residual disease, or complications, though CKC consistently removed deeper cones of tissue.¹³ However, a newer study using Swedish population data painted a different picture: women who had CKC showed a lower risk of recurrence than those who had LEEP, and CKC was associated with higher HPV clearance rates at 3, 6, and 12 months after treatment.¹⁴

The most plausible explanation for the discrepancy is cone depth. CKC tends to remove a deeper piece of cervical tissue, which can mean fewer positive margins and more complete removal of the transformation zone. But deeper excisions also carry greater reproductive risks, which creates a genuine tradeoff rather than a clear winner. For standard CIN 3 in a reproductive-age woman, LEEP remains the default choice in most guidelines. CKC is more commonly reserved for adenocarcinoma in situ or cases where the lesion extends deep into the cervical canal.

For adenocarcinoma in situ specifically, LEEP does have higher positive margin rates compared with CKC (about 44 percent versus 29 percent), though the residual disease and recurrence rates between the two methods are statistically similar.¹⁵

How LEEP Affects Future Pregnancies

This is the question that drives the most anxiety, particularly for younger women. The short answer is that LEEP does modestly increase the risk of preterm birth and related complications, and the magnitude of that risk correlates with how much tissue was removed.

A meta-analysis found that women with a history of LEEP had about twice the risk of premature rupture of membranes (roughly 5 percent versus 2.5 percent in untreated women), along with similarly elevated risks of preterm delivery and low birth weight.¹⁶ A separate meta-analysis confirmed the pattern, showing about double the odds of preterm delivery, premature membrane rupture, and low-birth-weight babies in women who had LEEP before pregnancy.¹⁷

Cone depth is the key variable here. A systematic review and meta-analysis published in the BMJ showed that preterm birth risk rises progressively with cone depth. Even shallow excisions (under 10 to 12 mm) carried about 1.5 times the risk of preterm delivery. Deeper cones amplified this: roughly twice the risk at 10 to 12 mm, nearly three times at 15 to 17 mm, and about five times the risk for excisions 20 mm or deeper.¹⁸ This is why surgeons try to minimize the depth of excision while still getting clear margins, and why young women considering future pregnancies should discuss how much tissue needs to come out.

One counterintuitive finding: a study comparing women who had immediate LEEP to those who had the procedure delayed found that delayed LEEP was actually associated with a higher preterm birth risk (about 30 percent higher).¹⁹ That study focused on CIN 2, but it suggests that delaying treatment in hopes of protecting future fertility may not help and could actually make things worse if a more advanced lesion eventually requires a deeper excision.

HPV Vaccination After LEEP

Getting vaccinated against HPV after LEEP is not a widely known recommendation, but the evidence for it has been building. In one study, women who received the HPV vaccine after LEEP had a recurrence rate of about 7 percent, versus roughly 17 percent in unvaccinated women. The benefit was even more pronounced for the most severe recurrences: CIN 3 or carcinoma in situ recurred in about 3 percent of vaccinated women compared with nearly 14 percent of those who were not vaccinated.²⁰

A larger study found that just 2.5 percent of vaccinated women developed recurrent CIN 2 or CIN 3 after LEEP, compared with 7.2 percent of unvaccinated women. Multivariate analysis showed that skipping vaccination after LEEP was an independent risk factor for recurrence, nearly tripling the odds.²¹ A Chinese observational study reported even starker numbers: about 2 percent recurrence in vaccinated women versus nearly 11 percent in unvaccinated women, with lack of vaccination carrying over twelve times the odds of recurrence in the statistical model.²²

The vaccine does not treat existing HPV infection, but it appears to help the immune system prevent re-infection or reactivation of vaccine-covered HPV types. If you have had LEEP for CIN 3 and have not been vaccinated, it is worth asking your clinician about it, regardless of your age.

Challenges in Postmenopausal Women

LEEP is not equally well-suited to all patients. Postmenopausal women present distinct challenges. A study comparing outcomes found that postmenopausal patients had a significantly higher positive margin rate after conization (about 21 percent versus 11 percent in premenopausal women) and lower agreement between the initial biopsy and the final surgical pathology. Ten of 101 postmenopausal women in the study were diagnosed with invasive cancer on the conization specimen, compared with just 2 of 202 premenopausal women.²³ The authors concluded that conization as a conservative treatment is less suitable for postmenopausal women with high-grade CIN, because the transformation zone has often receded into the cervical canal where it is harder to visualize and fully excise.

Supporting this concern, a study of 129 postmenopausal women who went on to have hysterectomy after conization found residual disease in over 43 percent of cases. LEEP (compared with cold-knife conization) was one of the factors associated with a higher rate of residual disease in this population.²⁴ For older women who have completed childbearing, hysterectomy may be the more reliable option when the lesion is not easily accessible.

Sexual Function After the Procedure

Fear that LEEP will permanently affect sexual function is common but appears largely unfounded. A study using validated questionnaires to measure sexual function and sexual distress before and after LEEP found no statistically significant changes in overall sexual function scores or in any individual component (desire, arousal, lubrication, orgasm, satisfaction, or pain). Rates of sexual distress also did not increase after the procedure.²⁵ Similarly, a randomized trial comparing LEEP with thermal ablation for CIN 2 and 3 found equivalent sexual function outcomes at six months.²⁶ That said, it takes several weeks for the cervix to heal, and most clinicians recommend avoiding intercourse for four to six weeks after the procedure.

Pain During the Procedure

LEEP is generally performed under local anesthesia in an outpatient setting. A randomized trial comparing lidocaine spray with the more standard submucosal injection found that both methods offered comparable pain control during the actual excision. The injection itself, though, caused more discomfort than the spray; baseline pain scores were comparable, but the post-anesthesia pain score was significantly higher in the injection group.²⁷ Most women report the experience as uncomfortable rather than severely painful. Common short-term side effects include mild cramping, spotting, and watery discharge that can last a few weeks.

One complication worth knowing about is cervical stenosis, where scar tissue narrows the opening of the cervix after healing. A systematic review found that LEEP was associated with somewhat less cervical stenosis than cold-knife conization, though the difference was not statistically significant.¹² When stenosis does occur, it can make future cervical screening difficult and may cause painful periods.

LEEP in Resource-Limited Settings

In wealthier health systems, the standard pathway for a woman with a high-grade screening result is a three-step process: abnormal Pap, colposcopy with biopsy to confirm the diagnosis, and then treatment at a later visit. Each step requires the patient to come back, and each gap creates an opportunity for someone to fall out of follow-up. In lower-resource settings, this dropout problem is serious enough to undermine the whole point of screening.

A “see-and-treat” approach collapses the process: if a woman’s screening result suggests high-grade disease, LEEP is performed at the same visit without waiting for biopsy confirmation. Studies from resource-constrained settings have shown that this approach is effective, with similar overtreatment rates compared with the traditional three-step process. It also significantly reduces cost and, critically, cuts the default rate, meaning fewer women are lost between diagnosis and treatment.²⁸ A separate study from a low-resource country confirmed that women with high-grade screening results can be effectively managed this way, since the large majority turn out to have CIN 2 or worse on final pathology, making immediate treatment appropriate.²⁹ The tradeoff is that some women with lower-grade disease get treated unnecessarily, but the overall benefit in preventing cancer through better follow-through outweighs that concern in settings where return visits cannot be guaranteed.